An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine
A 6-month, observational, post authorization safety study for the collection and evaluation of additional safety data on topiramate as a prophylactic treatment for migraines in adult patients. According to current European and international guidelines the safety and efficacy of drugs will be continuously monitored even after their approval and market circulation.The applicable methods of monitoring include: Observational studies, voluntarily reported adverse events, clinical trials of IV phase and Post Authorization Safety Studies ( PASS). Post Authorization Safety Studies (PASS) during the use of a product are a significant source of information regarding the action of the drug or a therapeutic method under the circumstances of every day clinical practice.
|Study Design:||Time Perspective: Prospective|
|Official Title:||An Open-label Observational Safety Study During Administration of Topiramate, for the Prophylaxis of Migraine|
- The primary outcome is effectiveness of topiramate based on the frequency of migraine headaches during the monotherapy with topiramate. [ Time Frame: Visit 1 and visit 5 ] [ Designated as safety issue: No ]
- Safety of topiramate (number of SAEs, AEs, Laboratory findings) [ Time Frame: Visits: 1-5 ] [ Designated as safety issue: No ]
|Study Start Date:||March 2005|
|Study Completion Date:||February 2007|
Previous studies have shown that topiramate is effective in preventing migraine headaches. This is a 6-month observational study to evaluate additional safety data of topiramate in the prevention of migraine in adult patients. The study duration is 6-months, with 5 study visits during the study. Administration of topiramate should be according to current Summary of Product Characteristics (SmPC) and daily clinical practice. The decision to prescribe topiramate is decided by the Health Care Professional and it is independent of the protocol. Based on the investigator's judgement, patients who enter the study should fulfill the criteria for administration of prophylactic treatment. In this study a total number of 80 patients with diagnosed migraine according to the criteria of the International Headache Society HIS (Cephalalgia 1998; 8 (Suppl7) :1-98) will participate. Patients who will be enrolled should be either male or female over 18 years of age, fulfilling the above mentioned criteria and who will agree to sign the written informed consent for the anonymous and confidential use of their medical data with their participation in the study. Methods of evaluation include tolerability, laboratory tests, vital signs and Body Weight and Body Mass Index (BMI). Efficacy by assessing migraine attacks, symptomatic medications and Headache Impact Test (HIT-6). Observational study - No investigational drug administered.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00297336
|Study Director:||Janssen-Cilag Pharmaceutica S.A.C.I. Clinical Trial||Janssen-Cilag Pharmaceutica S.A.C.I.|